Literature DB >> 21993875

Neurological syndrome after R-CHOP chemotherapy for a non-Hodgkin lymphoma: what is the diagnosis?

Dario Marino1, Patrizia Farina, Antonio Jirillo, Giuseppe De Franchis, Marco Simonetto, Savina Maria Luciana Aversa.   

Abstract

A 63-year-old man was admitted to our Oncology department for management of a follicular non-Hodgkin lymphoma, stage IV A FLIPI 5. The patient entered chemotherapy following the R-CHOP schedule, and a PET scan after three cycles showed partial remission. One week later he was admitted to our hospital after developing serious pain in his left arm resulting in an impaired function, right facial hemiplegia, and ophthalmoplegia. Neuroimaging studies and laboratory features were negative. Given his symptoms, we suspected Miller Fisher syndrome and the patient was administered high dose immunoglobulin, but showed no improvement. Finally, chemotherapy with methotrexate 3 g/mq was initiated, but his condition progressively worsened and the patient died 2 months later. We suggest that any patient with neurological symptoms who has received rituximab should undergo PCR analysis for all neurotropic viruses together with neurophysiological and neuroimaging studies.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21993875     DOI: 10.1007/s12185-011-0942-4

Source DB:  PubMed          Journal:  Int J Hematol        ISSN: 0925-5710            Impact factor:   2.490


  9 in total

Review 1.  Neoplastic meningitis.

Authors:  Beate Gleissner; Marc Charles Chamberlain
Journal:  Lancet Neurol       Date:  2006-05       Impact factor: 44.182

Review 2.  Enteroviral meningoencephalitis as complication of Rituximab therapy in a patient treated for diffuse large B-cell lymphoma.

Authors:  Sophie Servais; Jo Caers; Odile Warling; Nicolas Frusch; Frédéric Baron; Bernard De Prijck; Yves Beguin
Journal:  Br J Haematol       Date:  2010-04-14       Impact factor: 6.998

3.  Guillain-Barre syndrome in a patient with diffuse large B-cell lymphoma, and rituximab maintenance therapy. An association beyond anecdotal evidence?

Authors:  Alberto Carmona; Juan Domingo Alonso; Manuel de las Heras; Agustín Navarrete
Journal:  Clin Transl Oncol       Date:  2006-10       Impact factor: 3.405

4.  Development of psoriasis after B cell depletion with rituximab.

Authors:  Shouvik Dass; Edward M Vital; Paul Emery
Journal:  Arthritis Rheum       Date:  2007-08

5.  Enterovirus infection of neuronal cells post-Rituximab.

Authors:  Sorena Kiani-Alikhan; Ferdinandos Skoulidis; Ana Barroso; Gerard Nuovo; Ines Ushiro-Lumb; Judith Breuer; Andrew Lister; Frank Mattes
Journal:  Br J Haematol       Date:  2009-05-19       Impact factor: 6.998

6.  BK virus infection and neurologic dysfunctions in a patient with lymphoma treated with chemotherapy and rituximab.

Authors:  Angela Ferrari; Mario Luppi; Roberto Marasca; Leonardo Potenza; Monica Morselli; Francesco Volzone; Rita Santachiara; Fabio Forghieri; Patrizia Barozzi; Giuseppe Torelli
Journal:  Eur J Haematol       Date:  2008-05-27       Impact factor: 2.997

7.  Guillain-Barré syndrome after combined CHOP and rituximab therapy in non-Hodgkin lymphoma.

Authors:  Fabrizia Terenghi; Gianluca Ardolino; Eduardo Nobile-Orazio
Journal:  J Peripher Nerv Syst       Date:  2007-06       Impact factor: 3.494

8.  [Interstitial pneumonitis as a side effect of rituximab].

Authors:  J L Hans Kemming; Roel E P van Zeeland; Eric F Ullmann; E J M Vera Mattijssen
Journal:  Ned Tijdschr Geneeskd       Date:  2009

9.  Rituximab-induced acute thrombocytopenia: a case report and review of the literature.

Authors:  Jun Ho Yi; Seok Jin Kim; Hee Kyung Ahn; Su Jin Lee; Myung Hee Chang; Won Seog Kim
Journal:  Med Oncol       Date:  2008-06-10       Impact factor: 3.064

  9 in total
  1 in total

Review 1.  Biological Drugs in Guillain-Barré Syndrome: An Update.

Authors:  Nazgol Motamed-Gorji; Nassim Matin; Omidreza Tabatabaie; Piero Pavone; Catia Romano; Raffaele Falsaperla; Giovanna Vitaliti
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.